Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) Equity Ratio (2017 - 2025)

Cue Biopharma's Equity Ratio history spans 9 years, with the latest figure at 0.42 for Q3 2025.

  • For Q3 2025, Equity Ratio fell 26.05% year-over-year to 0.42; the TTM value through Sep 2025 reached 0.42, down 26.05%, while the annual FY2024 figure was 0.54, 9.81% down from the prior year.
  • Equity Ratio for Q3 2025 was 0.42 at Cue Biopharma, down from 0.45 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.81 in Q2 2021 and bottomed at 0.3 in Q1 2025.
  • The 5-year median for Equity Ratio is 0.63 (2023), against an average of 0.62.
  • The largest annual shift saw Equity Ratio increased 5.28% in 2021 before it plummeted 46.89% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.79 in 2021, then decreased by 8.37% to 0.72 in 2022, then dropped by 16.24% to 0.6 in 2023, then dropped by 9.81% to 0.54 in 2024, then fell by 23.0% to 0.42 in 2025.
  • Per Business Quant, the three most recent readings for CUE's Equity Ratio are 0.42 (Q3 2025), 0.45 (Q2 2025), and 0.3 (Q1 2025).